Dana-Farber Cancer Institute

Clinical Trials and Research for Mantle Cell Lymphoma

    In this section

    New Patient Appointments

    877-442-3324
    REQUEST AN APPOINTMENT

    Dana-Farber Cancer Institute is at the forefront of research in mantle cell lymphoma. We seek to advance more effective treatment options and reduce treatment side effects for patients with mantle cell lymphoma. Many of our trials are developed by our own team, who have identified needs or opportunities based on caring for patients or findings from our lab research. These investigator-initiated trials offer patients access to new and emerging therapeutics before they are available elsewhere. We offer trials for initial treatment as well as for relapsed disease with a focus on improving outcomes and limiting side effects.

    Featured Clinical Trials

    Newly-Diagnosed

    Trial 24-654: A randomized phase 2 study of bendamustine, rituximab, cytarabine (AraC) induction with zanubrutinib (BRAZAN) followed by zanubrutinib/rituximab +/- sonrotoclax maintenance in treatment-naïve mantle cell lymphoma
    Principal Investigator: Christine Ryan, MD

    Christine Ryan, MD, on the BRAZAN Trial for Mantle Cell Lymphoma

    Christine Ryan, MD, shares information on the BRAZAN trial, which is looking at a new first-line treatment approach for patients with newly diagnosed mantle cell lymphoma. Researchers are testing whether adding targeted oral medications to standard chemotherapy and maintenance treatment can help keep the lymphoma under control for longer.

    Trial 21-040: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma
    Principal Investigator: Austin Kim, MD

    Austin Kim, MD, on MAVO Trial for Untreated TP53-Mutated Mantle Cell Lymphoma

    Austin Kim, MD, provides an overview of the MAVO trial, which is studying a chemotherapy-free treatment approach for certain patients with previously untreated mantle cell lymphoma, especially those with a TP53 mutation. The trial combines acalabrutinib, venetoclax, and obinutuzumab, and is evaluating whether some patients may be able to stop treatment after a complete remission and MRD-negative result.

    Relapsed/Refractory

    Trial 26-048: A first-in-human, multicenter phase 1a/1b study to investigate safety, tolerability, and preliminary efficacy of LY4584180 in adult participants with previously treated hematologic malignancies
    Principal Investigator: David Qualls, MD

    Trial 25-264: A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma 
    Principal Investigator: Christine Ryan, MD

    Trial 24-444: A phase 1/2 open-label multi-centre master protocol to evaluate the safety and efficacy of AZD0486 monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies
    Principal Investigator: Matthew Davids, MD, MMSc  

    Trial 21-124: A multi-center single arm phase 2 study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
    Principal Investigator: Caron Jacobson, MD, MMSc

    Mantle Cell Lymphoma Clinical Trials

    877-338-7425
    Search Clinical Trials

    Ongoing Research in Mantle Cell Lymphoma

    Our research is guided by correlative science. This approach involves analyzing patient samples like tumor tissue, blood, and other body fluids collected before, during, and after treatment. This analysis generates data we use to try to understand why therapies have varying effects and how they impact cancer at a close-up level. These efforts help identify markers to predict treatment success, personalize care, and advance future cancer therapies. Our current focus areas in the lab include:

    • Developing tests to help match patients with the treatments from which they are most likely to benefit
    • Minimally invasive genetic analyses to characterize lymphoma biology and predict treatment response (cell-free DNA sequencing)
    • Developing functional tests that predict patient treatment outcomes based on the sensitivity of lymphoma cells from blood, bone marrow, or tissue biopsies when exposed to drugs in reproducible experimental conditions in the laboratory (BH3 profiling, single-cell biophysical profiling)
    • Demonstrating how the immune system contributes to disease behavior and drug sensitivity and how it can be utilized by novel treatments to improve patient outcomes
    • Characterizing the rare lymphoma cells that remain in the body of patients whose lymphoma is not detectable by standard laboratory and imaging studies and identifying novel therapeutic targets of these residual cancer cells. Such studies could guide future clinical trial efforts to prolong remissions and, ideally, convert remissions into cures